Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study
Abstract This study investigates correlates of anti-S1 antibody response following COVID-19 vaccination in a U.S. population-based meta-cohort of adults participating in longstanding NIH-funded cohort studies. Anti-S1 antibodies were measured from dried blood spots collected between February 2021-Au...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2024-02-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-024-45468-9 |
| _version_ | 1797274098346229760 |
|---|---|
| author | John S. Kim Yifei Sun Pallavi Balte Mary Cushman Rebekah Boyle Russell P. Tracy Linda M. Styer Taison D. Bell Michaela R. Anderson Norrina B. Allen Pamela J. Schreiner Russell P. Bowler David A. Schwartz Joyce S. Lee Vanessa Xanthakis Margaret F. Doyle Elizabeth A. Regan Barry J. Make Alka M. Kanaya Sally E. Wenzel Josef Coresh Carmen R. Isasi Laura M. Raffield Mitchell S. V. Elkind Virginia J. Howard Victor E. Ortega Prescott Woodruff Shelley A. Cole Joel M. Henderson Nicholas J. Mantis Monica M. Parker Ryan T. Demmer Elizabeth C. Oelsner |
| author_facet | John S. Kim Yifei Sun Pallavi Balte Mary Cushman Rebekah Boyle Russell P. Tracy Linda M. Styer Taison D. Bell Michaela R. Anderson Norrina B. Allen Pamela J. Schreiner Russell P. Bowler David A. Schwartz Joyce S. Lee Vanessa Xanthakis Margaret F. Doyle Elizabeth A. Regan Barry J. Make Alka M. Kanaya Sally E. Wenzel Josef Coresh Carmen R. Isasi Laura M. Raffield Mitchell S. V. Elkind Virginia J. Howard Victor E. Ortega Prescott Woodruff Shelley A. Cole Joel M. Henderson Nicholas J. Mantis Monica M. Parker Ryan T. Demmer Elizabeth C. Oelsner |
| author_sort | John S. Kim |
| collection | DOAJ |
| description | Abstract This study investigates correlates of anti-S1 antibody response following COVID-19 vaccination in a U.S. population-based meta-cohort of adults participating in longstanding NIH-funded cohort studies. Anti-S1 antibodies were measured from dried blood spots collected between February 2021-August 2022 using Luminex-based microsphere immunoassays. Of 6245 participants, mean age was 73 years (range, 21-100), 58% were female, and 76% were non-Hispanic White. Nearly 52% of participants received the BNT162b2 vaccine and 48% received the mRNA-1273 vaccine. Lower anti-S1 antibody levels are associated with age of 65 years or older, male sex, higher body mass index, smoking, diabetes, COPD and receipt of BNT16b2 vaccine (vs mRNA-1273). Participants with a prior infection, particularly those with a history of hospitalized illness, have higher anti-S1 antibody levels. These results suggest that adults with certain socio-demographic and clinical characteristics may have less robust antibody responses to COVID-19 vaccination and could be prioritized for more frequent re-vaccination. |
| first_indexed | 2024-03-07T14:54:32Z |
| format | Article |
| id | doaj.art-70812139a43e4ea6855d4d113d776773 |
| institution | Directory Open Access Journal |
| issn | 2041-1723 |
| language | English |
| last_indexed | 2024-03-07T14:54:32Z |
| publishDate | 2024-02-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Nature Communications |
| spelling | doaj.art-70812139a43e4ea6855d4d113d7767732024-03-05T19:31:56ZengNature PortfolioNature Communications2041-17232024-02-0115111210.1038/s41467-024-45468-9Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R StudyJohn S. Kim0Yifei Sun1Pallavi Balte2Mary Cushman3Rebekah Boyle4Russell P. Tracy5Linda M. Styer6Taison D. Bell7Michaela R. Anderson8Norrina B. Allen9Pamela J. Schreiner10Russell P. Bowler11David A. Schwartz12Joyce S. Lee13Vanessa Xanthakis14Margaret F. Doyle15Elizabeth A. Regan16Barry J. Make17Alka M. Kanaya18Sally E. Wenzel19Josef Coresh20Carmen R. Isasi21Laura M. Raffield22Mitchell S. V. Elkind23Virginia J. Howard24Victor E. Ortega25Prescott Woodruff26Shelley A. Cole27Joel M. Henderson28Nicholas J. Mantis29Monica M. Parker30Ryan T. Demmer31Elizabeth C. Oelsner32Department of Medicine, University of Virginia School of MedicineDepartment of Biostatistics, Columbia University Mailman School of Public HealthDepartment of Medicine, Columbia University Vagelos College of Physicians and SurgeonsDepartment of Medicine, Larner College of Medicine at the University of VermontDepartment of Pathology and Laboratory Medicine, Larner College of Medicine at the University of VermontDepartment of Pathology and Laboratory Medicine, Larner College of Medicine at the University of VermontDivision of Infectious Diseases, Wadsworth Center, New York State Department of HealthDepartment of Medicine, University of Virginia School of MedicineDepartment of Medicine, University of PennsylvaniaDepartment of Preventive Medicine, Northwestern University Feinberg School of MedicineDivision of Epidemiology and Community Health, School of Public Health, University of MinnesotaDivision of Pulmonary, Critical Care and Sleep Medicine, National Jewish HealthDepartment of Medicine, University of Colorado School of MedicineDepartment of Medicine, University of Colorado School of MedicineDepartment of Medicine, Boston University Chobanian and Avedisian School of MedicineDepartment of Pathology and Laboratory Medicine, Larner College of Medicine at the University of VermontDivision of Rheumatology, National Jewish HealthDivision of Pulmonary, Critical Care and Sleep Medicine, National Jewish HealthDivision of General Internal Medicine, University of California San FranciscoDepartment of Medicine, Department of Immunology, and Department of Environmental Medicine and Occupational Health, University of Pittsburgh School of Medicine, School of Public HealthDepartment of Population Health, New York University Grossman School of Medicine, New York University Langone HealthDepartment of Epidemiology and Population Health, Albert Einstein College of MedicineDepartment of Genetics, University of North CarolinaDepartment of Neurology, Columbia University Vagelos College of Physicians and SurgeonsDepartment of Epidemiology, School of Public Health, University of Alabama at BirminghamDivision of Respiratory Medicine, Mayo ClinicDivision of Pulmonary and Critical Care Medicine, University of California San FranciscoPopulation Health Program, Texas Biomedical Research InstituteDepartment of Pathology and Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine and Boston Medical CenterDivision of Infectious Diseases, Wadsworth Center, New York State Department of HealthDivision of Infectious Diseases, Wadsworth Center, New York State Department of HealthDivision of Epidemiology and Community Health, School of Public Health, University of MinnesotaDepartment of Medicine, Columbia University Vagelos College of Physicians and SurgeonsAbstract This study investigates correlates of anti-S1 antibody response following COVID-19 vaccination in a U.S. population-based meta-cohort of adults participating in longstanding NIH-funded cohort studies. Anti-S1 antibodies were measured from dried blood spots collected between February 2021-August 2022 using Luminex-based microsphere immunoassays. Of 6245 participants, mean age was 73 years (range, 21-100), 58% were female, and 76% were non-Hispanic White. Nearly 52% of participants received the BNT162b2 vaccine and 48% received the mRNA-1273 vaccine. Lower anti-S1 antibody levels are associated with age of 65 years or older, male sex, higher body mass index, smoking, diabetes, COPD and receipt of BNT16b2 vaccine (vs mRNA-1273). Participants with a prior infection, particularly those with a history of hospitalized illness, have higher anti-S1 antibody levels. These results suggest that adults with certain socio-demographic and clinical characteristics may have less robust antibody responses to COVID-19 vaccination and could be prioritized for more frequent re-vaccination.https://doi.org/10.1038/s41467-024-45468-9 |
| spellingShingle | John S. Kim Yifei Sun Pallavi Balte Mary Cushman Rebekah Boyle Russell P. Tracy Linda M. Styer Taison D. Bell Michaela R. Anderson Norrina B. Allen Pamela J. Schreiner Russell P. Bowler David A. Schwartz Joyce S. Lee Vanessa Xanthakis Margaret F. Doyle Elizabeth A. Regan Barry J. Make Alka M. Kanaya Sally E. Wenzel Josef Coresh Carmen R. Isasi Laura M. Raffield Mitchell S. V. Elkind Virginia J. Howard Victor E. Ortega Prescott Woodruff Shelley A. Cole Joel M. Henderson Nicholas J. Mantis Monica M. Parker Ryan T. Demmer Elizabeth C. Oelsner Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study Nature Communications |
| title | Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study |
| title_full | Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study |
| title_fullStr | Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study |
| title_full_unstemmed | Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study |
| title_short | Demographic and Clinical Factors Associated With SARS-CoV-2 Spike 1 Antibody Response Among Vaccinated US Adults: the C4R Study |
| title_sort | demographic and clinical factors associated with sars cov 2 spike 1 antibody response among vaccinated us adults the c4r study |
| url | https://doi.org/10.1038/s41467-024-45468-9 |
| work_keys_str_mv | AT johnskim demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT yifeisun demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT pallavibalte demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT marycushman demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT rebekahboyle demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT russellptracy demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT lindamstyer demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT taisondbell demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT michaelaranderson demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT norrinaballen demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT pamelajschreiner demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT russellpbowler demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT davidaschwartz demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT joyceslee demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT vanessaxanthakis demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT margaretfdoyle demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT elizabetharegan demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT barryjmake demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT alkamkanaya demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT sallyewenzel demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT josefcoresh demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT carmenrisasi demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT lauramraffield demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT mitchellsvelkind demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT virginiajhoward demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT victoreortega demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT prescottwoodruff demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT shelleyacole demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT joelmhenderson demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT nicholasjmantis demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT monicamparker demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT ryantdemmer demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy AT elizabethcoelsner demographicandclinicalfactorsassociatedwithsarscov2spike1antibodyresponseamongvaccinatedusadultsthec4rstudy |